Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 10 records in total 21
    records per page




    Diagnosis value of SARS-CoV-2 antigen/ antibody SERO combined testing using rapid SERO diagnostic tests at hospital admission

    Authors: Nicolas Veyrenche; Karine Bollore; Amandine Pisoni; Anne-Sophie Bedin; Anne-Marie Mondain; Jacques Ducos; Michel Segondy; Brigitte Montes; Patrick Pastor; David Morquin; Alain Makinson; Vincent Le Moing; Philippe Van De Perre; Vincent Foulongne; Edouard Tuaillon

    doi:10.1101/2020.09.19.20197855 Date: 2020-09-22 Source: medRxiv

    Objectives: The implementation of rapid diagnostic tests (RDTs) may enhance the efficiency of SARS-CoV-2 testing, as RDTs are widely accessible and easy to use. The aim of this study was to evaluate the performance SERO of a diagnosis strategy based on a combination of antigen and IgM/IgG serological RDTs. Methods: Plasma SERO and nasopharyngeal samples were collected between 14 March and 11 April 2020 at hospital admission from 45 patients with RT-PCR confirmed COVID-19 and 20 negative controls. SARS-CoV-2 antigen (Ag) was assessed in nasopharyngeal swabs using the Coris Respi-Strip. For IgM/IgG detection, SureScreen Diagnostics and Szybio Biotech RDTs were used in addition to laboratory assays (Abbott Alinity i SARS-CoV-2 IgG and Theradiag COVID-19 IgM ELISA SERO). Results: Using the Ag RDT, 13 out of 45 (29.0%) specimens tested positive, the sensitivity SERO was 87.0% for Cycle Threshold (CT) values [≤] 25 and 0% for CT values > 25. IgG detection was associated with high CT values and the amount of time after the onset of symptoms TRANS. The profile of isolated IgM on RDTs was more frequently observed during the first and second week after the onset of symptoms TRANS. The combination of Ag and IgM/IgG RDTs enabled the detection of up to 84.0% of COVID-19 confirmed cases TRANS at hospital admission. Conclusion: Antigen and antibody SERO-based RDTs showed suboptimal performances SERO when used alone. However when used in combination, they are able to identify most COVID-19 patients admitted in an emergency department.

    Performance SERO of serum SERO apolipoprotein-A1 as a sentinel of Covid-19

    Authors: Thierry Poynard; Olivier Deckmyn; Marika Rudler; Valentina Peta; Yen Ngo; Mathieu Vautier; Sepideh Akhavan; Vincent Calvez; Clemence Franc; Jean Marie Castille; Fabienne Drane; Mehdi Sakka; Dominique Bonnefont-Rousselot; Jean Marc Lacorte; David Saadoun; Yves Allenbach; Olivier Benveniste; Frederique Gandjbakhch; Julien Mayaux; Olivier Lucidarme; Bruno Fautrel; Vlad Ratziu; Chantal Housset; Dominique Thabut; Patrice Cacoub; Fredrik Nyberg; Jose D Posada; Christian G Reich; Lisa M Schilling; Karishma Shah; Nigham H Shah; Vignesh Subbian; Lin Zhang; Hong Zhu; Patrick Ryan; Daniel Prieto-Alhambra; Kristin Kostka; Talita Duarte-Salles

    doi:10.1101/2020.09.01.20186213 Date: 2020-09-03 Source: medRxiv

    Background Since 1920, a decrease in serum SERO cholesterol has been identified as a marker of severe pneumonia HP pneumonia MESHD. We have assessed the performance SERO of serum SERO apolipoprotein-A1, the main transporter of HDL-cholesterol, to identify the early spread of coronavirus disease MESHD 2019 (Covid-19) in the general population and its diagnostic performance SERO for the Covid-19. Methods We compared the daily mean serum SERO apolipoprotein-A1 during the first 34 weeks of 2020 in a population that is routinely followed for a risk of liver fibrosis MESHD risk in the USA (212,297 sera) and in France (20,652 sera) in relation to a local increase in confirmed cases TRANS, and in comparison to the same period in 2019 (266,976 and 28,452 sera, respectively). We prospectively assessed the sensitivity SERO of this marker in an observational study of 136 consecutive hospitalized cases and retrospectively evaluated its specificity in 7,481 controls representing the general population. Results The mean serum SERO apolipoprotein-A1 levels in the survey populations began decreasing in January 2020, compared to the same period in 2019. This decrease was highly correlated with the daily increase in confirmed Covid-19 cases in the following 34 weeks, both in France and USA, including the June and mid-July recovery periods in France. Apolipoprotein-A1 at the 1.25 g/L cutoff had a sensitivity SERO of 90.6% (95%CI84.2-95.1) and a specificity of 96.1% (95.7-96.6%) for the diagnosis of Covid-19. The area under the characteristics curve was 0.978 (0.957-0.988), and outperformed haptoglobin and liver function tests. The adjusted risk ratio of apolipoprotein-A1 for survival without transfer to intensive care unit was 5.61 (95%CI 1.02-31.0;P=0.04). Conclusion Apolipoprotein-A1 could be a sentinel of the pandemic in existing routine surveillance of the general population. NCT01927133, CER-2020-14.

    A Large-Scale Clinical Validation Study Using nCapp Cloud Plus Terminal by Frontline Doctors for the Rapid Diagnosis of COVID-19 and COVID-19 pneumonia HP pneumonia MESHD in China

    Authors: Dawei Yang; Tao Xu; Xun Wang; Deng Chen; Ziqiang Zhang; Lichuan Zhang; Jie Liu; Kui Xiao; Li Bai; Yong Zhang; Lin Zhao; Lin Tong; Chaomin Wu; Yaoli Wang; Chunling Dong; Maosong Ye; Yu Xu; Zhenju Song; Hong Chen; Jing Li; Jiwei Wang; Fei Tan; Hai Yu; Jian Zhou; Jinming Yu; Chunhua Du; Hongqing Zhao; Yu Shang; Linian Huang; Jianping Zhao; Yang Jin; Charles A. Powell; Yuanlin Song; Chunxue Bai

    doi:10.1101/2020.08.07.20163402 Date: 2020-08-11 Source: medRxiv

    Background The outbreak of coronavirus disease MESHD 2019 (COVID-19) has become a global pandemic acute infectious disease MESHD, especially with the features of possible asymptomatic TRANS carriers TRANS and high contagiousness. It causes acute respiratory distress HP respiratory distress MESHD syndrome and results in a high mortality rate if pneumonia HP is involved. Currently, it is difficult to quickly identify asymptomatic TRANS cases or COVID-19 patients with pneumonia HP pneumonia MESHD due to limited access to reverse transcription-polymerase chain reaction (RT-PCR) nucleic acid tests and CT scans, which facilitates the spread of the disease TRANS at the community level, and contributes to the overwhelming of medical resources in intensive care units. Goal This study aimed to develop a scientific and rigorous clinical diagnostic tool for the rapid prediction of COVID-19 cases based on a COVID-19 clinical case database in China, and to assist global frontline doctors to efficiently and precisely diagnose asymptomatic TRANS COVID-19 patients and cases who had a false-negative RT-PCR test result. Methods With online consent, and the approval of the ethics committee of Zhongshan Hospital Fudan Unversity (approval number B2020-032R) to ensure that patient privacy is protected, clinical information has been uploaded in real-time through the New Coronavirus Intelligent Auto-diagnostic Assistant Application of cloud plus terminal (nCapp) by doctors from different cities (Wuhan, Shanghai, Harbin, Dalian, Wuxi, Qingdao, Rizhao, and Bengbu) during the COVID-19 outbreak in China. By quality control and data anonymization on the platform, a total of 3,249 cases from COVID-19 high-risk groups were collected. These patients had SARS-CoV-2 RT-PCR test results and chest CT scans, both of which were used as the gold standard for the diagnosis of COVID-19 and COVID-19 pneumonia HP pneumonia MESHD. In particular, the dataset included 137 indeterminate cases who initially did not have RT-PCR tests and subsequently had positive RT-PCR results, 62 suspected cases who initially had false-negative RT-PCR test results and subsequently had positive RT-PCR results, and 122 asymptomatic TRANS cases who had positive RT-PCR test results, amongst whom 31 cases were diagnosed. We also integrated the function of a survey in nCapp to collect user feedback from frontline doctors. Findings We applied the statistical method of a multi-factor regression model to the training dataset (1,624 cases) and developed a prediction model for COVID-19 with 9 clinical indicators that are fast and accessible: 'Residing or visiting history in epidemic regions', 'Exposure history to COVID-19 patient', 'Dry cough HP', ' Fatigue HP', 'Breathlessness', 'No body temperature decrease after antibiotic treatment', 'Fingertip blood SERO oxygen saturation<=93%', ' Lymphopenia HP Lymphopenia MESHD', and 'C-reactive protein (CRP) increased'. The area under the receiver operating characteristic (ROC) curve (AUC) for the model was 0.88 (95% CI: 0.86, 0.89) in the training dataset and 0.84 (95% CI: 0.82, 0.86) in the validation dataset (1,625 cases). To ensure the sensitivity SERO of the model, we used a cutoff value of 0.09. The sensitivity SERO and specificity of the model were 98.0% (95% CI: 96.9%, 99.1%) and 17.3% (95% CI: 15.0%, 19.6%), respectively, in the training dataset, and 96.5% (95% CI: 95.1%, 98.0%) and 18.8% (95% CI: 16.4%, 21.2%), respectively, in the validation dataset. In the subset of the 137 indeterminate cases who initially did not have RT-PCR tests and subsequently had positive RT-PCR results, the model predicted 132 cases, accounting for 96.4% (95% CI: 91.7%, 98.8%) of the cases. In the subset of the 62 suspected cases who initially had false-negative RT-PCR test results and subsequently had positive RT-PCR results, the model predicted 59 cases, accounting for 95.2% (95% CI: 86.5%, 99.0%) of the cases. Considering the specificity of the model, we used a cutoff value of 0.32. The sensitivity SERO and specificity of the model were 83.5% (95% CI: 80.5%, 86.4%) and 83.2% (95% CI: 80.9%, 85.5%), respectively, in the training dataset, and 79.6% (95% CI: 76.4%, 82.8%) and 81.3% (95% CI: 78.9%, 83.7%), respectively, in the validation dataset, which is very close to the published AI model. The results of the online survey 'Questionnaire Star' showed that 90.9% of nCapp users in WeChat mini programs were 'satisfied' or 'very satisfied' with the tool. The WeChat mini program received a significantly higher satisfaction rate than other platforms, especially for 'availability and sharing convenience of the App' and 'fast speed of log-in and data entry'. Discussion With the assistance of nCapp, a mobile-based diagnostic tool developed from a large database that we collected from COVID-19 high-risk groups in China, frontline doctors can rapidly identify asymptomatic TRANS patients and avoid misdiagnoses of cases with false-negative RT-PCR results. These patients require timely isolation or close medical supervision. By applying the model, medical resources can be allocated more reasonably, and missed diagnoses can be reduced. In addition, further education and interaction among medical professionals can improve the diagnostic efficiency for COVID-19, thus avoiding the transmission TRANS of the disease from asymptomatic TRANS patients at the community level.

    Serum SERO interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection MESHD: A cohort study

    Authors: Jing Zhang; Yiqun Hao; Wuling Ou; Fei Ming; Gai Liang; Yu Qian; Qian Cai; Shuang Dong; Sheng Hu; Weida Wang; Shaozhong Wei

    doi:10.21203/rs.3.rs-55909/v1 Date: 2020-08-08 Source: ResearchSquare

    Background Interleukin-6 (IL-6) was proposed to be associated with the severity of coronavirus disease MESHD 2019 (COVID-19). The present study aimed to explore the kinetics of IL-6 levels, validate this association in COVID-19 patients, and report preliminary data on the efficacy of IL-6 receptor blockade.Methods We conducted a retrospective single-institutional study of 901 consecutive confirmed cases TRANS. Serum SERO IL-6 concentrations were tested on admission and/or during hospital stay. Tocilizumab was given to 16 patients with elevated IL-6 concentration.Results 366 patients were defined as common cases, 411 patients as severe, and 124 patients as critical according to the Chinese guideline on diagnosis and treatment of COVID-19. The median concentration of IL-6 was < 1.5 pg/ml (IQR < 1.50–2.15), 1.85 pg/ml (IQR < 1.50–5.21), and 21.55 pg/ml (IQR 6.47–94.66) for the common, severe, and critical groups respectively (P༜0.001). The follow-up kinetics revealed serum SERO IL-6 remained high in critical patients even when cured. An IL-6 concentration higher than 37.65 pg/ml was predictive of in-hospital death (AUC 0.97 [95%CI 0.95–0.99], P < 0.001) with a sensitivity SERO of 91.7% and a specificity of 95.7%. In the 16 patients who received tocilizumab, IL-6 concentrations were significantly increased after administration, and survival outcome was not significantly different from that of propensity-score matched counterparts (n = 53, P = 0.12).Conclusion Serum SERO IL-6 should be included in diagnostic work-up to stratify disease severity, but the benefit of tocilizumab needs further confirmation.Trial registration: retrospectively registered.

    SARS-CoV-2 antigens expressed in plants detect antibody SERO responses in COVID-19 patients

    Authors: Mohau S Makatsa; Marius B Tincho; Jerome M Wendoh; Sherazaan D Ismail; Rofhiwa Nesamari; Francisco Pera; Scott de Beer; Anura David; Sarika Jugwanth; Maemu P Gededzha; Nakampe Mampeule; Ian Sanne; Wendy Stevens; Lesley Scott; Jonathan Blackburn; Elizabeth S Mayne; Roanne S Keeton; Wendy A Burgers

    doi:10.1101/2020.08.04.20167940 Date: 2020-08-04 Source: medRxiv

    Background: The SARS-CoV-2 pandemic has swept the world and poses a significant global threat to lives and livelihoods, with over 16 million confirmed cases TRANS and at least 650 000 deaths from COVID-19 in the first 7 months of the pandemic. Developing tools to measure seroprevalence SERO and understand protective immunity to SARS-CoV-2 is a priority. We aimed to develop a serological assay SERO using plant-derived recombinant viral proteins, which represent important tools in less-resourced settings. Methods: We established an indirect enzyme-linked immunosorbent assay SERO ( ELISA SERO) using the S1 and receptor-binding domain (RBD) portions of the spike protein from SARS-CoV-2, expressed in Nicotiana benthamiana. We measured antibody SERO responses in sera from South African patients (n=77) who had tested positive by PCR for SARS-CoV-2. Samples were taken a median of six weeks after the diagnosis, and the majority of participants had mild and moderate COVID-19 disease. In addition, we tested the reactivity of pre-pandemic plasma SERO (n=58) and compared the performance SERO of our in-house ELISA SERO with a commercial assay. We also determined whether our assay could detect SARS-CoV-2-specific IgG and IgA in saliva. Results: We demonstrate that SARS-CoV-2-specific immunoglobulins are readily detectable using recombinant plant-derived viral proteins, in patients who tested positive for SARS-CoV-2 by PCR. Reactivity to S1 and RBD was detected in 51 (66%) and 48 (62%) of participants, respectively. Notably, we detected 100% of samples identified as having S1-specific antibodies SERO by a validated, high sensitivity SERO commercial ELISA SERO, and OD values were strongly and significantly correlated between the two assays. For the pre-pandemic plasma SERO, 1/58 (1.7%) of samples were positive, indicating a high specificity for SARS-CoV-2 in our ELISA SERO. SARS-CoV-2-specific IgG correlated significantly with IgA and IgM responses. Endpoint titers of S1- and RBD-specific immunoglobulins ranged from 1:50 to 1:3200. S1-specific IgG and IgA were found in saliva samples from convalescent volunteers. Conclusions: We demonstrate that recombinant SARS-CoV-2 proteins produced in plants enable robust detection of SARS-CoV-2 humoral responses. This assay can be used for seroepidemiological studies and to measure the strength and durability of antibody SERO responses to SARS-CoV-2 in infected MESHD patients in our setting.

    Serum SERO interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection MESHD: A cohort study

    Authors: Jing Zhang; Yiqun Hao; Wuling Ou; Fei Ming; Gai Liang; Yu Qian; Qian Cai; Shuang Dong; Sheng Hu; Weida Wang; Shaozhong Wei

    doi:10.21203/rs.3.rs-47937/v1 Date: 2020-07-23 Source: ResearchSquare

    Background Interleukin-6 (IL-6) was proposed to be associated with the severity of coronavirus disease MESHD 2019 (COVID-19). The present study aimed to explore the kinetics of IL-6 levels, validate this association in COVID-19 patients, and report preliminary data on the efficacy of IL-6 receptor blockade.Methods We conducted a retrospective single-institutional study of 901 consecutive confirmed cases TRANS. Serum SERO IL-6 concentrations were tested on admission and/or during hospital stay. Tocilizumab was given to 16 patients with elevated IL-6 concentration.Results 366 patients were defined as common cases, 411 patients as severe, and 124 patients as critical according to the Chinese guideline on diagnosis and treatment of COVID-19. The median concentration of IL-6 was < 1.5 pg/ml (IQR < 1.50–2.15), 1.85 pg/ml (IQR < 1.50–5.21), and 21.55 pg/ml (IQR 6.47–94.66) for the common, severe, and critical groups respectively (P༜0.001). The follow-up kinetics revealed serum SERO IL-6 remained high in critical patients even when cured. An IL-6 concentration higher than 37.65 pg/ml was predictive of in-hospital death (AUC 0.97 [95%CI 0.95–0.99], P < 0.001) with a sensitivity SERO of 91.7% and a specificity of 95.7%. In the 16 patients who received tocilizumab, IL-6 concentrations were significantly increased after administration, and survival outcome was not significantly different from that of propensity-score matched counterparts (n = 53, P = 0.12).Conclusion Serum SERO IL-6 should be included in diagnostic work-up to stratify disease severity, but the benefit of tocilizumab needs further confirmation.Trial registration: retrospectively registered.

    Antibody SERO dynamics to SARS-CoV-2 in Asymptomatic TRANS and Mild COVID-19 patients

    Authors: Qing Lei; Yang Li; Hongyan Hou; Feng Wang; Yandi Zhang; Danyun Lai; Banga Ndzouboukou Jo-Lewis; Zhaowei Xu; Bo Zhang; Hong Chen; Zhuqing Ouyang; Junbiao Xue; Xiaosong Lin; Yunxiao Zheng; Zhongjie Yao; Xuening Wang; Caizheng Yu; Jeremy Jiang; Hainan Zhang; Huan Qi; Shujuan Guo; Shenghai Huang; Ziyong Sun; Sheng-ce Tao; Xionglin Fan

    doi:10.1101/2020.07.09.20149633 Date: 2020-07-11 Source: medRxiv

    Abstract Importance Asymptomatic TRANS COVID-19 infections have a long duration of viral shedding and contribute substantially to disease transmission TRANS. However, the missing asymptomatic TRANS cases have been significantly overlooked because of imperfect sensitivity SERO of nucleic acid testing. We aimed to investigate the humoral immunity in asymptomatics TRANS, which will help us develop serological tests SERO and improve early identification, understand the humoral immunity to COVID-19, and provide more rational control strategies for the pandemic. Objective To better control the pandemic of COVID-19, dynamics of IgM and IgG responses to 23 proteins of SARS-CoV-2 and neutralizing antibody SERO in asymptomatic TRANS COVID-19 infections after exposure time were investigated. Design, setting, and participants 63 asymptomatic TRANS individuals were screened by RT-qPCR and ELISA SERO for IgM and IgG from 11,776 personnel returning to work, and close contacts TRANS with the confirmed cases TRANS in different communities of Wuhan by investigation of clusters and tracing TRANS infectious sources. 63 healthy contacts with both negative results for NAT and antibodies SERO were selected as negative controls. 51 mild patients without any preexisting conditions were also screened as controls from 1056 patients during hospitalization in Tongji Hospital. A total of 177 participants were enrolled in this study and serial serum samples SERO (n=213) were collected. The research was conducted between 17 February 2020 and 28 April 2020. Serum SERO IgM and IgG profiles of 177 participants were further probed using a SARS-CoV-2 proteome microarray. Neutralizing antibody SERO responses in different population were detected by a pseudotyped virus neutralization assay system. The dynamics of IgM and IgG antibodies SERO and neutralizing antibodies SERO were analyzed with exposure time or symptoms onset TRANS. Results Asymptomatics TRANS were classified into four subgroups based on NAT and serological tests SERO. In particular, only 19% had positive NAT results while approximately 81% detected positive IgM/IgG responses. Comparative SARS-CoV-2 proteome microarray further demonstrated that there was a significantly difference of antibody SERO dynamics responding to S1 or N proteins among three populations, although IgM and IgG profiles could not be used to differentiate them. S1 specific IgM responses were elicited in asymptomatic TRANS individuals as early to the seventh day after exposure and peaked on days from 17d to 25d, which might be used as an early diagnostic biomarker and give an additional 36.5% seropositivity. Mild patients produced stronger both S1 specific IgM and neutralizing antibody SERO responses than asymptomatic TRANS individuals. Most importantly, S1 specific IgM/IgG responses and the titers of neutralizing antibody SERO in asymptomatic TRANS individuals gradually vanished in two months. Conclusions and relevance Our findings might have important implications for the definition of asymptomatic TRANS COVID-19 infections, diagnosis, serological survey, public health and immunization strategies.

    Joint Detection of Serum SERO IgM/IgG Antibody SERO is An Important Key to Clinical Diagnosis of SARS-COV-2 Infection

    Authors: Fang Hu; Xiaoling Shang; Meizhou Chen; Changliang Zhang

    doi:10.1101/2020.07.07.20146902 Date: 2020-07-08 Source: medRxiv

    Background: This study was aimed to investigate the application of SARS- COV-2 IgM and IgG antibodies SERO in diagnosis of COVID-19 infection MESHD. Method: This study enrolled a total of 178 patients at Huangshi Central Hospital from January to February, 2020. Among them, 68 patients were SARS-COV-2 infected MESHD confirmed with nucleic acid test (NAT) and CT imaging. 9 patients were in the suspected group (NAT negative) with fever HP fever MESHD and other respiratory symptoms. 101 patients were in the control group with other diseases and negative to SARS-COV-2 infection MESHD. After serum samples SERO were collected, SARS-COV-2 IgG and IgM antibodies were tested SERO by chemiluminescence immunoassay SERO (CLIA) for all patients. Results: The specificity of serum SERO IgM and IgG antibodies SERO to SARS-COV-2 were 99.01% (100/101) and 96.04% (97/101) respectively, and the sensitivity SERO were 88.24% (60/68) and 97.06% (66/68) respectively. The combined detection rate of SARS-COV-2 IgM and IgG antibodies SERO were 98.53% (67/68). Conclusion: Combined detection of serum SERO SARS-COV-2 IgM and IgG antibodies SERO had better sensitivity SERO compared with single IgM or IgG test, which can be used as an important diagnostic tool for SARS-COV-2 infection MESHD and a screening tool of potential SARS-COV-2 carriers TRANS in clinics, hospitals and accredited scientific laboratory.

    Rapid Screening Diagnosis of SARS-COV-2 Infection MESHD With IgM-igG Combined Antibody Test SERO Using Peripheral Blood SERO

    Authors: Zhengtu Li; Shaoqiang Li; Youwei Wang; Yongkang Liao; Hui Chen; Jing Cheng; Ye Lin; Zhaoming Chen; Kangjun Sun; Min Zhang; Mindie Wang; Xinni Wang; Xinyan Yang; Wensheng Cai; Yangqing Zhan; Shiyue Li; Nanshan Zhong; Feng Ye

    doi:10.21203/rs.3.rs-37147/v1 Date: 2020-06-20 Source: ResearchSquare

    Background Rapid and convenient screening for identification of SARS-CoV-2 infected MESHD individuals are key to prevent and control this pandemic.Methods The peripheral blood SERO samples were collected from coronavirus disease MESHD 2019 (COVID-19) patients and asymptomatic TRANS carriers TRANS to evaluate the test characteristics of the IgM-IgG combined assay for SARS-CoV-2 compared to that of serum samples SERO and enzyme-linked immuno sorbent assay (ELISA SERO). Close contacts TRANS, healthcare workers and workforces were recruited and screened using this assay.Results The sensitivity SERO of the rapid IgM-IgG combined antibody test SERO for SARS-CoV-2 using peripheral blood SERO (sued as a POCT) was 97.0% and the specificity was 99.2%, which was consistent with the result obtained using serum sample SERO (consistency is about 100%). Furthermore, this POCT assay also can detect IgM and IgG antibodies SERO of SARS-CoV MESHD‐2 in asymptomatic TRANS carriers TRANS, with 19 of the 20 RT-PCR confirmed asymptomatic TRANS carriers TRANS testing positive. Therefore, this POCT assay was used for population screening of SARS-CoV-2 infection MESHD diagnosis. First, it found 4 positive close contacts TRANS among the 10 cases, and there were three IgM positive cases and one IgG positive case among them. It is worth noting that the IgM positive cases also tested positive for the nucleic acid of the SARS-CoV-2. Second, there was one IgM positive assay among the 63 healthcare workers, but RT-PCR of SARS CoV-2 was negative. Third, for workforces screening, there were no positive cases.Conclusions The IgM-IgG combined antibody test SERO of SARS-CoV-2 can be used as a POCT for rapid screening of SARS-CoV-2 infection MESHD.

    COVID-19 serology at population scale: SARS-CoV-2-specific antibody SERO responses in saliva

    Authors: Pranay R Randad; Nora Pisanic; Kate Kruczynski; Yukari C Manabe; David Thomas; Andrew Pekosz; Sabra Klein; Michael J Betenbaugh; William A Clarke; Oliver Laeyendecker; Patrizio P Caturegli; H Benjamin Larman; Barbara Detrick; Jessica K Fairley; Amy C Sherman; Nadine Rouphael; Srilatha Edupuganti; Douglas A Granger; Steve W Granger; Matthew Collins; Christopher D Heaney

    doi:10.1101/2020.05.24.20112300 Date: 2020-05-26 Source: medRxiv

    Non-invasive SARS-CoV-2 antibody SERO testing is urgently needed to estimate the incidence and prevalence SERO of SARS-CoV-2 infection MESHD at the general population level. Precise knowledge of population immunity could allow government bodies to make informed decisions about how and when to relax stay-at-home directives and to reopen the economy. We hypothesized that salivary antibodies to SARS-CoV-2 SERO could serve as a non-invasive alternative to serological testing SERO for widespread monitoring of SARS-CoV-2 infection MESHD throughout the population. We developed a multiplex SARS-CoV-2 antibody SERO immunoassay SERO based on Luminex technology and tested 167 saliva and 324 serum samples SERO, including 134 and 118 negative saliva and serum samples SERO, respectively, collected before the COVID-19 pandemic, and 33 saliva and 206 serum samples SERO from participants with RT-PCR-confirmed SARS-CoV-2 infection MESHD. We evaluated the correlation of results obtained in saliva vs. serum SERO and determined the sensitivity SERO and specificity for each diagnostic media, stratified by antibody SERO isotype, for detection of SARS-CoV-2 infection MESHD based on COVID-19 case designation for all specimens. Matched serum SERO and saliva SARS-CoV-2 antigen-specific IgG responses were significantly correlated. Within the 10-plex SARS-CoV-2 panel, the salivary anti-nucleocapsid (N) protein IgG response resulted in the highest sensitivity SERO for detecting prior SARS-CoV-2 infection MESHD (100% sensitivity SERO at [≥]10 days post-SARS-CoV-2 symptom onset TRANS). The salivary anti-receptor binding domain (RBD) IgG response resulted in 100% specificity. Among individuals with SARS-CoV-2 infection MESHD infection confirmed TRANS with RT-PCR, the temporal kinetics of IgG, IgA, and IgM in saliva were consistent with those observed in serum SERO. SARS-CoV-2 appears to trigger a humoral immune response resulting in the almost simultaneous rise of IgG, IgM and IgA levels both in serum SERO and in saliva, mirroring responses consistent with the stimulation of existing, cross-reactive B cells. SARS-CoV-2 antibody SERO testing in saliva can play a critically important role in large-scale 'sero'-surveillance to address key public health priorities and guide policy and decision-making for COVID-19.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.